{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:59:52Z","timestamp":1781067592849,"version":"3.54.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Romidepsin is a class I-selective histone deacetylase (HDAC) inhibitor indicated for the treatment of adult patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy and for adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Despite its clinical use, large-scale safety data remain limited. This study leverages the FDA Adverse Event Reporting System (FAERS) database to characterize romidepsin-associated adverse events (AEs) in real-world settings, aiming to enhance clinical risk management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the FAERS database, spanning from January 2014 to March 2025, served as the basis for this analysis. To evaluate the association between romidepsin and AEs, multiple disproportionality analyses were employed, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Within the specified reporting period, 17,448,626 AE reports were recorded in the FAERS database, of which 1,285 events were associated with romidepsin. Based on four calculation methods, 101 preferred terms (PTs) related to romidepsin were determined. Common AEs included thrombocytopenia, pyrexia, anemia, electrocardiogram QT prolonged, and infections, aligning with the drug label. In addition, some unanticipated major AEs were detected, including cardiotoxicities beyond QT prolongation (acute cardiac failure, atrial fibrillation, sinus tachycardia, mitral valve incompetence, and bundle branch block left) alongside other significant AEs: hepatic failure, amenorrhea, mental status changes, glomerular filtration rate decreased, embolism, and retinal detachment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides a systematic evaluation of AEs associated with romidepsin, confirming its established safety profile and identifying several emerging safety concerns in a real-world setting. These findings offer valuable insights to assist clinicians and pharmacists in better-managing romidepsin\u2019s safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1694602","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:29:05Z","timestamp":1781065745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world pharmacovigilance study of romidepsin based on FDA adverse event reporting system database"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuqin","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second People's Hospital","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, China Pharmaceutical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital, Pingtan Comprehensive Experimental Area","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maohua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital, Pingtan Comprehensive Experimental Area","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2017.1341487","article-title":"The discovery and development of romidepsin for the treatment of T-cell lymphoma","volume":"12","author":"Smolewski","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"B4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10147-016-1045-2","article-title":"T-cell lymphomas, a challenging disease: Types, treatments, and future","volume":"22","author":"Ma","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: A report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: Results of the Ro-CHOP phase III study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B12","article-title":"T-Cell Lymphomas (Version 2.2025)","year":"2025"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01687","article-title":"Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: Final analysis of the Ro-CHOP trial","volume":"42","author":"Camus","year":"2024","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03076-6","article-title":"Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: A phase 1b\/2a trial","volume":"30","author":"Horwitz","year":"2024","journal-title":"Nat Med"},{"key":"B17","article-title":"ROMIDEPSIN injection, for intravenous use: Full prescribing information","year":"2021"},{"key":"B18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12911-020-1053-z","article-title":"Mining and visualizing high-order directional drug interaction effects using the FAERS database","volume":"20","author":"Yao","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.70389\/PJS.100082","article-title":"Transparency in the reporting of Artificial Intelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Premier J Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107966","article-title":"Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study","volume":"196","author":"Chen","year":"2024","journal-title":"Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35193","article-title":"Postmarketing adverse events of tamoxifen in male and female patients with breast cancer","volume":"156","author":"Ke","year":"2025","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12885-023-11201-w","article-title":"A real-world disproportionality analysis of Rucaparib: Post-marketing pharmacovigilance data","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1473756","article-title":"Disproportionality analysis of oesophageal toxicity associated with oral bisphosphonates using the FAERS database (2004-2023)","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33417","article-title":"Adverse events associated with eteplirsen: A disproportionality analysis using the 2016\u20132023 FAERS data","volume":"10","author":"Dai","year":"2024","journal-title":"Heliyon"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2025.104824","article-title":"Deduplicating the FDA adverse event reporting system with a novel application of network-based grouping","volume":"165","author":"Kreimeyer","year":"2025","journal-title":"J BioMed Inf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14215","article-title":"Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system","volume":"29","author":"Shu","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-025-01573-2","article-title":"Strategies and challenges in coding ambiguous information using MedDRA(\u00ae): An exploration among Norwegian pharmacovigilance officers","volume":"48","author":"Garmann","year":"2025","journal-title":"Drug Saf"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"84","author":"Hu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27529","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021787","article-title":"New insights into the biology of T-cell lymphomas","volume":"144","author":"Iqbal","year":"2024","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.732727","article-title":"Efficacy and treatment-related adverse events of romidepsin in PTCL clinical studies: A systematic review and meta-analysis","volume":"8","author":"Du","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: Final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2461199","article-title":"Infectious complications associated with immune and targeted anti-cancer therapies: A retrospective study of the FDA adverse events reporting system (FAERS)","volume":"24","author":"Alsowaida","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv596","article-title":"Epstein-Barr virus reactivation in extranodal natural killer\/T-cell lymphoma patients: A previously unrecognized serious adverse event in a pilot study with romidepsin","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01602-10","article-title":"Interplay between PKC\u03b4 and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation","volume":"85","author":"Tsai","year":"2011","journal-title":"J Virol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83533-0","article-title":"Essential role of PKCdelta in histone deacetylase inhibitor-induced Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells","volume":"89","author":"Lee","year":"2008","journal-title":"J Gen Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105063","article-title":"Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK\/T cell lymphoma; Potential implications for HDACi-mediated fatal complications","volume":"189","author":"Kim","year":"2021","journal-title":"Antiviral Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00116-08","article-title":"Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors","volume":"82","author":"Countryman","year":"2008","journal-title":"J Virol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(15)00097-6","article-title":"Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicentre phase 2 trial","volume":"2","author":"Tan","year":"2015","journal-title":"Lancet Haematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp270","article-title":"Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)","volume":"21","author":"Molife","year":"2010","journal-title":"Ann Oncol"},{"key":"B42","article-title":"Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms","volume":"8","author":"Sandor","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.187617","article-title":"A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"103","author":"Strati","year":"2018","journal-title":"Haematologica"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000498905","article-title":"Romidepsin-bendamustine combination for relapsed\/refractory T cell lymphoma","volume":"141","author":"Nachmias","year":"2019","journal-title":"Acta Haematologica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1515937","article-title":"A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; The Canadian cancer trials group LY.15 study\u2020","volume":"60","author":"Reiman","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-2152","article-title":"Romidepsin plus liposomal doxorubicin is safe and effective in patients with relapsed or refractory T-cell lymphoma: Results of a phase I dose-escalation study","volume":"26","author":"Vu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009445","article-title":"Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma","volume":"7","author":"Kalac","year":"2023","journal-title":"Blood Adv"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1158\/1078-0432.Ccr-05-2689","article-title":"Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors","volume":"12","author":"Shah","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3816\/CGC.2006.n.018","article-title":"A phase II study of depsipeptide in refractory metastatic renal cell cancer","volume":"5","author":"Stadler","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-2095","article-title":"Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-13-0109","article-title":"Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel","volume":"19","author":"Noonan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.467","article-title":"Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin","volume":"4","author":"Sager","year":"2015","journal-title":"Cancer Med"},{"key":"B53","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am J Transl Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1160082","article-title":"Use of class I histone deacetylase inhibitor romidepsin in combination regimens","volume":"57","author":"Petrich","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.semcancer.2025.05.008","article-title":"HDAC inhibitors: Cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury","volume":"113","author":"To","year":"2025","journal-title":"Semin Cancer Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05691-2","article-title":"A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors","volume":"103","author":"Li","year":"2024","journal-title":"Ann Hematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13712","article-title":"Class I HDAC modulates angiotensin II-induced fibroblast migration and mitochondrial overactivity","volume":"52","author":"Huynh","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.025857","article-title":"Histone deacetylase 6 inhibitor JS28 prevents pathological gene expression in cardiac myocytes","volume":"11","author":"Ngo","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118367","article-title":"Histone deacetylases in myocardial infarction: Orchestrating programmed cell death pathways and emerging therapeutic opportunities","volume":"190","author":"Wen","year":"2025","journal-title":"Biomedicine Pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2024.116957","article-title":"A novel histone deacetylase inhibitor Se-SAHA attenuates isoproterenol-induced heart failure via antioxidative stress and autophagy inhibition","volume":"487","author":"Cheng","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1634\/theoncologist.7-1-65","article-title":"The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern","volume":"7","author":"Keefe","year":"2002","journal-title":"Oncologist"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1348-9","article-title":"Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study","volume":"20","author":"Yavas","year":"2012","journal-title":"Support Care Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1226-5","article-title":"Electrocardiographic findings of palonosetron in cancer patients","volume":"20","author":"Gonullu","year":"2012","journal-title":"Support Care Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1078155216673229","article-title":"Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature","volume":"24","author":"Rivers","year":"2018","journal-title":"J Oncol Pharm Practice: Off Publ Int Soc Oncol Pharm Practitioners"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"B66","article-title":"ISTODAX (romidepsin) for injection, for intravenous use: Full prescribing information","year":"2021"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"B68","article-title":"Romidepsin","volume-title":"LiverTox: clinical and research information on drug-induced liver injuryed","year":"2012"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281875","article-title":"Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed\/refractory T-cell lymphoma: results from a phase I\/II open-label multicenter study","volume":"109","author":"Iyer","year":"2024","journal-title":"Haematologica"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-1412","article-title":"Phase I and pharmacokinetic study of romidepsin in patients with cancer and hepatic dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study","volume":"26","author":"Connolly","year":"2020","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.415","article-title":"HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness","volume":"8","author":"Leyk","year":"2017","journal-title":"Cell Death Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00477","article-title":"Targeting relevant HDACs to support the survival of cone photoreceptors in inherited retinal diseases: Identification of a potent pharmacological tool with In vitro and In vivo efficacy","volume":"67","author":"Carullo","year":"2024","journal-title":"J Med Chem"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2147\/clep.S154914","article-title":"The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study","volume":"10","author":"Mart\u00edn-Merino","year":"2018","journal-title":"Clin Epidemiol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1622736","article-title":"Drug-induced Sweet's syndrome: pharmacovigilance insights from FAERS with a cross-database consistency assessment in VigiBase via LASSO and multivariable logistic regression","volume":"16","author":"Xie","year":"2025","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.7326\/m23-2063","article-title":"The safety of outpatient health care: Review of electronic health records","volume":"177","author":"Levine","year":"2024","journal-title":"Ann Internal Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1694602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:29:06Z","timestamp":1781065746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1694602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":75,"alternative-id":["10.3389\/fonc.2026.1694602"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1694602","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1694602"}}